PAVmed Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative)

Stockholders' Equity and Common Stock Purchase Warrants (Details Narrative) - USD ($)												1 Months Ended				3 Months Ended	12 Months Ended
	Dec. 27, 2018	Aug. 22, 2018	Jun. 12, 2018	Jun. 02, 2018	Apr. 05, 2018	Feb. 08, 2018	Jan. 25, 2018	Jan. 23, 2018	Jan. 19, 2018	Jan. 11, 2018	Apr. 28, 2016	Jan. 31, 2020	Oct. 31, 2019	Mar. 31, 2018	Jan. 31, 2018	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Jul. 31, 2018	Mar. 15, 2018	Dec. 31, 2017
Common stock, shares authorized																	100,000,000	100,000,000
Common stock, par value per share	$ 0.92																$ 0.001	$ 0.001
Common stock, shares issued																	40,478,861	27,142,979
Common stock, shares outstanding																	40,478,861	27,142,979			14,551,234
Number of shares issued																	5,480,000	2,649,818
Gross proceeds from issuance of common stock																	$ 5,480,000
Debt conversion share issued																	7,773,110
Debt issuance date																	Dec. 27, 2018
Number of stock issued under Employee Stock Purchase Plan																	82,772
Gross proceeds from issuance initial public offering																		$ 4,388,099
Exercise price per share																		$ 5.00
Calculated aggregate estimated fair value																		$ 96,480
Stock-based compensation																	$ 1,570,652	$ 1,228,699
Lucid Diagnostics Inc [Member]
Common stock, shares issued																	10,000,000	10,000,000
Common stock, shares outstanding																	10,000,000	10,000,000
Majority ownership interest percentage																	81.875%	81.875%
Solys Diagnostics Inc. [Member]
Common stock, shares issued																	9,189,190	9,189,190
Common stock, shares outstanding																	9,189,190	9,189,190
Majority ownership interest percentage																	90.3235%	90.3235%
Equity Subscription Rights Offering [Member]
Common stock, par value per share			$ 7.1
Common stock, shares issued			17,509,654
Common stock, shares outstanding			17,509,654
Maximum equity subscriptions paid			9,000,000
Purchase of common stock unit price per share			$ 1.15
Subscriptions offering costs			$ 200,000
Employee Stock Purchase Plan [Member]
Number of stock issued under Employee Stock Purchase Plan													82,772
Senior Secured Convertible Note [Member]
Common stock, par value per share																	$ 0.89
Debt conversion share issued																	7,773,110
Debt issuance date																	Dec. 27, 2018	Nov. 04, 2019
Senior Secured Note [Member]
Number of shares issued	600,000
Debt conversion share issued	550,440
Placement Agency Agreement [Member]
Number of shares issued																530,000
Gross proceeds from issuance of common stock																$ 5,480,000
Placement agent fees and legal fees																$ 101,098
Underwriting Agreement [Member] \| Dawson James Securities, Inc., [Member]
Common stock, shares issued									362,292
Number of shares issued							234,540	2,415,278	2,415,278
Value of common stock per share									$ 1.80
Underwriter's discount							$ 4,388,099
Gross proceeds from issuance initial public offering							$ 113,438
Individual Investors [Member]
Number of shares issued																4,950,000
Common Stock [Member]
Number of shares issued																5,480,000
Equity Subscription Rights Offering [Member]
Number of shares issued			9,000,000
Gross proceeds from issuance of common stock			$ 10,400,000
Equity subscription period date			Jun. 07, 2018
Equity subscription purchases description			The equity subscription provided for the purchase of a common stock unit at a $1.15 per unit, with each such unit comprised of one share of common stock of the Company and one Series Z Warrant, and immediately separated upon issue into its underlying components.
Commissions and fees			$ 1,000,000
Series Z Warrants [Member]
Number of shares issued																	20,000
Additional paid-in capital			$ 2,100,000
Value of common stock per share					$ 1.66
Exercise price per share					$ 3.00
Warrant to purchase common stock		53,000															16,815,039	16,815,039
Warrant issued and outstanding																	16,815,039	16,815,039
Warrant exercise price description																	Upon issue, a Series Z Warrant is exercisable to purchase one share of common stock of the Company at an exercise price of $1.60 per share, effective June 1, 2018. The Series Z Warrant exercise price was initially $3.00 per share through May 31, 2018. On May 15, 2018, the Company's board of directors approved a reduction to the Series Z Warrant exercise price to $1.60 per share, effective June 1, 2018, upon completion of the period-of-notice to the holders of Series Z Warrants then issued and outstanding. See herein below for further information with respect to the modification expense recognized in connection with the Series Z Warrant exercise price adjustment. The Series Z Warrant $1.60 exercise price is not subject-to further adjustment, unless by action of the PAVmed Inc board of directors, or the effect of stock dividends, stock splits or similar events affecting the common stock of the Company.
Warrant maturity date																	Apr. 30, 2024
Redemption price per share for outstanding warrants																	$ 0.01
Weighted average closing price of common stock																	9.00
Modification of the Series Z warrant agreement				$ 1,140,995
Calculated aggregate estimated fair value		$ 1,060			$ 3,304,377
Expected volatility					55.00%
Risk free rate					2.70%
Expected term (years)					2 years 8 months 12 days
Dividend yield					0.00%
Series Z Warrants [Member] \| Minimum [Member]
Exercise price per share				$ 1.60
Series Z Warrants [Member] \| Maximum [Member]
Exercise price per share				$ 3.00
Series Z Warrants [Member] \| Series A & Series A -1 Exchange Offer March 15,2018 Exchange Date [Member]
Warrant to purchase common stock																				2,739,190
Series Z Warrants [Member] \| Series W Warrants Offer-to-Exchange [Member]
Warrant to purchase common stock					5,075,849
Warrant modification expense					$ 766,456
Calculated aggregate estimated fair value					$ 3,304,377
Series Z Warrants [Member] \| Equity Subscription Rights Offering [Member]
Warrant to purchase common stock			9,000,000
Series Z Warrants [Member] \| UPO Offer-to-Exchange [Member]
Warrant to purchase common stock		53,000
Calculated aggregate estimated fair value		$ 3,180
Underwritten Public Offering [Member]
Number of shares issued															2,649,818
Series W Warrants [Member]
Number of shares issued										20,000
Value of common stock per share					$ 1.66
Gross proceeds from issuance initial public offering						$ 50,520
Number of warrant exercised						34,345
Exercise price per share					$ 5.00	$ 2.00				$ 2.00							$ 5.00	$ 5.00
Proceeds from warrant exercises						$ 68,690
Warrant to purchase common stock					10,151,682												381,818	381,818
Warrant issued and outstanding																	381,818	381,818
Redemption price per share for outstanding warrants										0.01
Weighted average closing price of common stock										$ 10.00
Warrant exercisable date																		Oct. 28, 2016
Warrant expiry date										Feb. 08, 2018								Jan. 29, 2022
Calculated aggregate estimated fair value					$ 7,903,000
Expected volatility					55.00%
Risk free rate					25.00%
Expected term (years)					3 years 9 months 18 days
Dividend yield					0.00%
Series W Warrants [Member] \| Unit Purchase Options [Member]
Exercise price per share		$ 1.60
Common Stock [Member]
Number of shares issued														274,257				2,649,818
Number of stock issued under Employee Stock Purchase Plan																	82,772
Series S Warrants [Member]
Number of shares issued																	2,660,000
Exercise price per share																	$ 0.01
Proceeds from warrant exercises														$ 2,743
Warrant to purchase common stock																	1,199,383	1,199,383
Warrant issued and outstanding																	1,199,383	1,199,383
Series S Warrants [Member] \| Subsequent Event [Member]
Number of warrant exercised												1,199,383
Proceeds from warrant exercises												$ 11,994
Series B Convertible Preferred Stock [Member]
Number of shares issued
Number of stock issued under Employee Stock Purchase Plan
Convertible preferred stock, shares issued upon conversion																			33,325	499,334
Unit Purchase Options [Member]
Value of common stock per share											$ 5.00
Exercise price per share		$ 5.50									$ 5.50
Warrant to purchase common stock		53,000
Warrant issued and outstanding		53,000
Modification of the Series Z warrant agreement		$ 2,120
Warrant expiry date		Jan. 29, 2021
Fair value assumptions amount											$ 105,100
Expected volatility											50.00%
Risk free rate											1.28%
Expected term (years)											4 years 7 months 6 days
Dividend yield											0.00%
Unit Purchase Options [Member] \| IPO [Member]
Number of shares issued											53,000
Non-controlling Interest [Member] \| Lucid Diagnostics Inc [Member]
Majority ownership interest percentage																	18.125%	18.125%
Non-controlling Interest [Member] \| Solys Diagnostics Inc. [Member]
Majority ownership interest percentage																	9.6765%	9.6765%